Our Active Trials
~ Breast Cancer
~ Ovarian Cancer
~ Other Cancers
Questions About Trials
Questions About Immunity
Clinical Trials |
||
| For more information regarding our trials please call our Research Coordinator Nicole Bates | 206.543.6620 | nbates@u.washington.edu |
||
Volunteer |
||
|
Cancer immunology is an extremely new and exciting field. Scientists and research physicians are constantly gaining greater understanding about the way the immune system interacts with cancer. They are discovering and developing new, immune-based treatments that are now becoming the standard of care in addition to surgery, chemotherapy, and radiation. These treatments impact everyone who is affected by the cancer – from families and organizations in the local community to researchers and patients throughout the world. Do you feel you might be eligible for a study? Please read below to learn about studies that are currently open, clinical trial participation, and current research. |
|
| We are looking for women who have been diagnosed with Cancer in the last five years and who are willing to donate blood for cancer research. Click Here for more information. | ||
Breast Cancer |
|
| A Phase I Study of Infusion of HER-2/neu Specific T Cells in Patients with Advanced Stage HER-2/neu Expressing Cancers Who Have Received a HER-2/neu Vaccine Physician Description | Patient Description |
|
| A Phase I Safety and Efficacy Trial of a DNA Plasmid Based Vaccine Encoding the HER-2/neu (HER2) Intracellular Domain in Subjects with HER-2/neu-Overexpressing Tumors Physician Description | Patient Description |
|
| Phase II study of a HER-2/neu (HER2) intracellular domain (ICD) peptide-based vaccine administered to Stage IIIB and IV HER2 positive breast cancer patients receiving trastuzumab monotherapy Physician Description | Patient Description |
|
| A Phase I-II study of Denileukin Diftitox (ONTAK) in patients with advanced refractory breast cancer. Physician Description | Patient Description |
|
Ovarian Cancer |
|
| A Phase I Study of Infusion of HER-2/neu Specific T Cells in Patients with Advanced Stage HER-2/neu Expressing Cancers Who Have Received a HER-2/neu Vaccine Physician Description | Patient Description |
|
| A Phase I Safety and Efficacy Trial of a DNA Plasmid Based Vaccine Encoding the HER-2/neu (HER2) Intracellular Domain in Subjects with HER-2/neu-Overexpressing Tumors Physician Description | Patient Description |
|
| Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK Administered to Patients with Advanced Stage Ovarian Cancer Physician Description | Patient Description |
|
| A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) with Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Resistant Epithelial Ovarian Cancer Physician Description | Patient Description |
|
| A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination with Chemotherapy to Subjects with Advanced Solid Malignancies Study Information |
|
Other Cancers |
|
| A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination with Chemotherapy to Subjects with Advanced Solid Malignancies Study Information |
|